Investors of PROCEPT BioRobotics Corporation Targeting Class Action for Significant Losses

Investor Alert: PROCEPT BioRobotics Corporation Class Action Lawsuit

In recent developments, investors of PROCEPT BioRobotics Corporation (NASDAQ: PRCT) are facing a significant opportunity for legal recourse following a sharp decline in the company’s stock price. A class action lawsuit has been initiated by the law firm Hagens Berman Sobol Shapiro LLP, aiming to represent those who acquired PROCEPT shares during a specified period when misleading sales practices were allegedly in play.

Background

The lawsuit stems from a concerning trend regarding PROCEPT's sales of its single-use handpiece, a vital component of its Aquablation therapy designed for patients with enlarged prostate. Throughout a period spanning from February 28, 2024, to February 25, 2026, investors report that they suffered substantial losses primarily due to inadequacies in the company’s communication regarding the health of its sales operations.

Hagens Berman has initiated an investigation into claims that PROCEPT, alongside other defendants, violated federal securities laws by not fully disclosing the true state of their business operations. As reported, the company engaged in questionable sales strategies aimed at increasing short-term revenue but compromising future profits, ultimately leading to a decline in investor confidence.

Key Allegations

One of the main allegations under scrutiny is the company’s use of a bulk order discount program which incentivized customers to place larger orders than necessary, thereby artificially inflating quarterly sales figures. This practice raised alarms when it began to emerge that sales figures did not correspond with actual customer demand, resulting in excess inventory and a significant downturn in sales.

Investors first caught wind of this misalignment when PROCEPT reported its dismal financial results for Q2 2025 on August 6, 2025, revealing a stark underperformance in handpiece sales that fell well below consensus estimates. The subsequent announcement for Q3 2025 on November 4 continued this alarming trend, with management slashing annual sales guidance and admitting mishandling of customer inventories.

On February 25, 2026, the company further exacerbated its predicament by admitting to a cumulative excess of over 10,000 handpieces in customer inventories, with sales having plummeted 30% sequentially. This revelation forced the company to eliminate its discount program, a move seen as an acknowledgment of the damage inflicted by previous sales tactics.

The Impact on Investors

As a direct consequence of these disclosures, PROCEPT’s stock witnessed a staggering drop, losing over 48% of its value from its peak in August 2025. Shareholders are now encouraged to document their losses and consider participation in the class action lawsuit led by Hagens Berman. The investigation aims to explore the extent of the potential misconduct and whether the firm failed to uphold transparency in communication with investors.

Call to Action

Hagens Berman is actively seeking investors with substantial losses linked to PROCEPT. The firm emphasizes the importance of collective action in such cases, urging affected shareholders to come forward and explore their legal options. Additionally, individuals with relevant non-public information are encouraged to consider whistleblower protections available through the SEC Whistleblower program, which provides rewards for successfully reported information that leads to recoveries.

For more insights regarding this case or to learn how to proceed, interested parties can visit www.hbsslaw.com/cases/procept-biorobotics-corporation-prct-securities-class-action or contact Hagens Berman at (844) 916-0895.

About Hagens Berman

Hagens Berman Sobol Shapiro LLP is renowned for its commitment to corporate accountability and represents a wide range of plaintiffs, including investors and whistleblowers. With a solid track record of securing substantial settlements in litigation cases, the firm invites those affected to take steps to seek justice and uphold their rights in the face of corporate negligence.